The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure.
about
The impact of regular physical activity on fatigue, depression and quality of life in persons with multiple sclerosisPEGylation of Interferon-β-1aMemory rehabilitation for people with multiple sclerosisAcupuncture for multiple sclerosisPsychological interventions for multiple sclerosisMultidisciplinary rehabilitation for adults with multiple sclerosisRole of health-related quality of life measures in the routine care of people with multiple sclerosisWeb-based interventions in multiple sclerosis: the potential of tele-rehabilitationPatient reported outcome measures in neurogenic bladderTherapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosisAn update on the evidence base for peginterferon β1a in the treatment of relapsing-remitting multiple sclerosisThe feasibility of collecting information from people with Multiple Sclerosis for the UK MS Register via a web portal: characterising a cohort of people with MSThe effect of rhythmic-cued motor imagery on walking, fatigue and quality of life in people with multiple sclerosis: A randomised controlled trial.Possible clinical outcome measures for clinical trials in patients with multiple sclerosisWeb-based physiotherapy for people moderately affected with Multiple Sclerosis; quantitative and qualitative data from a randomized, controlled pilot study.Outcome Measures in Clinical Trials for Multiple Sclerosis.Psychometric properties of the SCOPA-AUT Brazilian Portuguese version.Longitudinal proxy measurements in multiple sclerosis: patient-proxy agreement on the impact of MS on daily life over a period of two years.The size of the treatment effect: do patients and proxies agree?Relationship between working hours and power of attention, memory, fatigue, depression and self-efficacy one year after diagnosis of clinically isolated syndrome and relapsing remitting multiple sclerosis.Retinal nerve fiber layer thickness in subgroups of multiple sclerosis, measured by optical coherence tomography and scanning laser polarimetry.Peginterferon beta-1a reduces disability worsening in relapsing-remitting multiple sclerosis: 2-year results from ADVANCE.Validity of korean versions of the multiple sclerosis impact scale and the multiple sclerosis international quality of life questionnaireMulti-centre parallel arm randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based cognitive behavioural approach to managing fatigue in people with multiple sclerosisTesting the feasibility and acceptability of using the Nintendo Wii in the home to increase activity levels, vitality and well-being in people with multiple sclerosis (Mii-vitaliSe): protocol for a pilot randomised controlled study.A group-delivered self-management program reduces spasticity in people with multiple sclerosis: A randomized, controlled pilot trial.Effects of a DVD-delivered exercise intervention on physical function in older adults with multiple sclerosis: A pilot randomized controlled trial.Analysis of the psychometric properties of the Multiple Sclerosis Impact Scale-29 (MSIS-29) in relapsing-remitting multiple sclerosis using classical and modern test theory.Evaluation of an integrated multidisciplinary approach in multiple sclerosis care: A prospective, randomized, controlled studyA task-oriented circuit training in multiple sclerosis: a feasibility study.A computer-based screening method for distress in patients with multiple sclerosis: a feasibility studyLong-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis.Effect of exercising at minimum recommendations of the multiple sclerosis exercise guideline combined with structured education or attention control education - secondary results of the step it up randomised controlled trial.Patient-reported outcomes and survival in multiple sclerosis: A 10-year retrospective cohort study using the Multiple Sclerosis Impact Scale-29.Living with chronic illness scale: international validation of a new self-report measure in Parkinson's disease.Validity and reliability of the Finnish version of the Multiple Sclerosis Impact Scale-29.Validity and reliability of the Fatigue Severity Scale in Finnish multiple sclerosis patientsDoes the relationship between physical activity and quality of life differ based on generic versus disease-targeted instruments?Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies.The Canadian survey of health, lifestyle and ageing with multiple sclerosis: methodology and initial results.
P2860
Q21245612-2A2C34CC-962E-416C-9B1A-3FC33A0965CBQ22241420-05DD9AD1-A242-429F-A7AF-2A0BF518A258Q24186011-2D24F7F8-28CC-4BDA-A1DD-62257A3F9C4EQ24241139-D82F9953-D128-4FBE-90D0-8C5E508030E8Q24244909-6AC9A3A3-F8D3-47B6-B038-5C07F07C2B39Q24245311-8A936C13-F071-42A4-A5C3-44B23928AB78Q24805196-885E3A69-9036-4701-9CCB-2E4C4141E2FBQ26745688-D2C98E52-2E9C-43C4-A2B1-F918764D52F0Q26767322-64B70DE7-B3D5-4554-B736-13887E0881A3Q28066677-74B5AA58-E3BB-48C2-8785-E27642FAC568Q28076879-281B9440-AAC8-4D11-A6FB-F0CC47B1EA56Q28727760-9A8BFD97-FF60-4FFC-912A-A6F2AD586B1CQ30386624-AD9DFFF1-FA1D-4DF6-9389-F41AB955FFC8Q30433837-2EF04B87-0083-48B0-B0C2-C972A5D086A1Q30791242-1A5D421A-9E46-4D10-BC6C-79BDDE5E242BQ31160866-C7C441AD-2688-4D54-B6B4-DFDF101ED3C9Q33158086-32DD68B7-A81A-4567-BBD7-6B6E6CE6D3F0Q33321691-2BC2944D-283C-4D8B-A9AA-2F08E934448AQ33421586-5BE31915-1398-4097-8AE0-328CFCF623D9Q33553474-A0FD72A9-98A3-4AB1-98D4-93FFBA5EA70FQ33576003-0E0A5529-425B-4C91-AA8F-3ABF44E3CE11Q33589958-5B43E55C-5B54-4ED7-93B6-6D543B0E43FCQ33594772-AB631476-D5B0-4A9A-AB57-3A8FBE54F9BBQ33606260-62885E04-1849-480D-8442-999889E98499Q33639572-0B2CAD8A-1BEA-4B5F-8E3C-0FB5E946C2EFQ33692249-38224218-A221-425B-8224-F3D2105E8A7EQ33692505-A9A88DBF-5914-4A7E-A198-8E6F72320632Q33692762-66193E1B-17E0-413E-BF4A-27C591D0D21DQ33692767-0D0292CD-1791-47B7-BFB7-39043D1C7DFBQ33761057-38864E3E-C1E5-41BC-AE7B-F7B65276236EQ33807826-C6DED96F-7058-4BD4-AB02-810C0FF4ACCDQ33825885-F798A72D-CFA5-41CA-946F-6F57B1440C9FQ33830925-4FD6E24F-4277-4905-A325-FBE29EDF39E7Q33887859-0C979917-254E-42CF-A568-D210221AD451Q33917273-DA2CBD4A-2BBF-45C5-AA95-4062786CE5E7Q33917369-68F41A0D-DB04-441E-82C2-B934839066A4Q33917437-F663ED84-66D5-43A0-8116-1AAE436A02DBQ33946092-2C209DB4-2B3D-4226-83DE-D0619D00621BQ33965239-5D71B6FB-93F8-4755-A463-FA16BF395FF1Q33996378-9C7BE4E0-2530-4FC1-B6E8-7EF5DE904BA5
P2860
The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure.
@ast
The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure.
@en
The Multiple Sclerosis Impact Scale
@nl
type
label
The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure.
@ast
The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure.
@en
The Multiple Sclerosis Impact Scale
@nl
prefLabel
The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure.
@ast
The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure.
@en
The Multiple Sclerosis Impact Scale
@nl
P2093
P356
P1433
P1476
The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure.
@en
P2093
P304
P356
10.1093/BRAIN/124.5.962
P407
P577
2001-05-01T00:00:00Z